The Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: “The Example of Meta-Analyses Evaluating the Efficacy and Safety of Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis”

The Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: “The Example of Meta-Analyses Evaluating the Efficacy and Safety of Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis”

Nonrandomized studies are usually excluded from systematic reviews. This could lead to loss of a considerable amount of information on rare diseases. In this article, we explore the impact of excluding nonrandomized studies on the generalizability of meta-analyses results on mucopolysaccharidosis (M...

Full description

Bibliographic Details
Main Authors: Miguel Sampayo-Cordero, Bernat Miguel-Huguet, Andrea Malfettone, José Manuel Pérez-García, Antonio Llombart-Cussac, Javier Cortés, Almudena Pardo, Jordi Pérez-López
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Molecular Biosciences
Subjects:
systematic review
mucopolysaccharidosis
enzyme replacement therapy
rare disease
nonrandomized study
meta-analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fmolb.2021.690615/full

Internet

https://www.frontiersin.org/articles/10.3389/fmolb.2021.690615/full

Similar Items